A Phase 1b/2 Study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations

被引：0

作者：

Aftimos, Philippe ^{[1
]}

Oliveira, Mafalda ^{[2
]}

Punie, Kevin ^{[3
]}

Boni, Valentina ^{[4
]}

Hamilton, Erika ^{[5
]}

Gucalp, Ayca ^{[6
]}

Shah, Payal ^{[7
]}

Mina, Lida ^{[8
]}

Sharma, Priyanka ^{[9
]}

Bauman, Lisa ^{[10
]}

Campeau, Eric ^{[11
]}

Attwell, Sarah ^{[11
]}

Snyder, Margo ^{[10
]}

Norek, Karen ^{[11
]}

Czibere, Akos ^{[12
]}

Yu, Yanke ^{[13
]}

Silverman, Michael H. ^{[10
]}

Lakhotia, Sanjay ^{[10
]}

Domchek, Susan ^{[7
]}

Litton, Jennifer ^{[14
]}

Robson, Mark ^{[6
]}

机构：

[1] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium

[2] Vall dHebron Inst Oncol, Barcelona, Spain

[3] UZ Leuven, Leuven, Belgium

[4] START, Madrid, Spain

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[7] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[8] Banner MD Anderson Canc Ctr, Gilbert, AZ USA

[9] Univ Kansas, Ctr Canc, Westwood, KS USA

[10] Zenith Epigenet, San Francisco, CA USA

[11] Zenith Epigenet, Calgary, AB, Canada

[12] Pfizer, Cambridge, MA USA

[13] Pfizer, La Jolla, CA USA

[14] Univ Texas MD Anderson, Houston, TX USA

来源：

CANCER RESEARCH | 2021年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PS11-10

引用

页数：1

共 50 条

[1] A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.
Aftimos, Philippe Georges
Oliveira, Mafalda
Punie, Kevin
Boni, Valentina
Hamilton, Erika P.
Gucalp, Ayca
Shah, Payal D.
de Miguel, Maria J.
Sharma, Priyanka
Bauman, Lisa
Campeau, Eric
Attwell, Sarah
Snyder, Margo
Norek, Karen
Johnson, Emily
Silverman, Michael H.
Lakhotia, Sanjay
Domchek, Susan M.
Litton, Jennifer Keating
Robson, Mark E.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] A phase 1 study of the BET inhibitor ZEN003694 in combination with the MEK1/2 inhibitor binimetinib in solid tumors with RAS pathway alterations and triple-negative breast cancer (NCI number 10449).
Torrado, Carlos
Rai, Kunal
Moawad, Mona
Dumbrava, Ecaterina Elena
Fu, Siqing
Hong, David S.
Karp, Daniel D.
Meric-Bernstam, Funda
Naing, Aung
Pohlmann, Paula R.
Ahnert, Jordi Rodon
Tsimberidou, Apostolia Maria
Yap, Timothy A.
Said, Rabih
Pelosof, Lorraine Cheryl
Piha-Paul, Sarina A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.
Litton, Jennifer Keating
Beck, Joseph Thaddeus
Jones, Jason M.
Andersen, Jay
Blum, Joanne Lorraine
Mina, Lida A.
Brig, Raymond
Danso, Michael A.
Yuan, Yuan
Abbattista, Antonello
Noonan, Kay
Chakrabarti, Jayeta
Czibere, Akos
Symmans, William Fraser
Telli, Melinda L.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Fuzuloparib with or without apatinib in HER2-metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial
Li, H.
Liu, J.
Liu, Y.
Ouyang, Q.
Wang, S.
Tong, Z.
Teng, Y.
Sun, T.
Wang, X.
Cheng, J.
Zhou, X.
Fanfan, L.
Yan, M.
Nie, J.
Ye, C.
Shao, Z-M.
Wang, Y.
Yang, X.
Song, E.
ANNALS OF ONCOLOGY, 2024, 35 (06) : 574 - 575
[5] Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study
Nicholas C. Turner
A. Douglas Laird
Melinda L. Telli
Hope S. Rugo
Audrey Mailliez
Johannes Ettl
Eva-Maria Grischke
Lida A. Mina
Judith Balmaña
Peter A. Fasching
Sara A. Hurvitz
Julia F. Hopkins
Lee A. Albacker
Jijumon Chelliserry
Ying Chen
Umberto Conte
Andrew M. Wardley
Mark E. Robson
npj Breast Cancer, 9
[6] Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study
Turner, Nicholas C.
Laird, A. Douglas
Telli, Melinda L.
Rugo, Hope S.
Mailliez, Audrey
Ettl, Johannes
Grischke, Eva-Maria
Mina, Lida A.
Balmana, Judith
Fasching, Peter A.
Hurvitz, Sara A.
Hopkins, Julia F.
Albacker, Lee A.
Chelliserry, Jijumon
Chen, Ying
Conte, Umberto
Wardley, Andrew M.
Robson, Mark E.
NPJ BREAST CANCER, 2023, 9 (01)
[7] Talazoparib (TALA) for patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC): Characteristics of patients who experienced hematologic toxicity in the phase III EMBRACA trial
Hurvitz, S. A.
Rugo, H. S.
Ettl, J.
Martin, M.
Roche, H.
Lee, K-H.
Goodwin, A.
Usari, T.
Lanzalone, S.
Guenzel, C. A.
Blum, J.
Litton, J. K.
ANNALS OF ONCOLOGY, 2021, 32 : S482 - S482
[8] A phase 1b/2 study of ramucirumab in combination with emibetuzumab in patients with advanced solid tumors
Bendell, Johanna
Fuchs, Charles
Voss, Martin
Bauer, Todd M.
Choueiri, Toni K.
Drilon, Alexander
Thorn, Katharine
Wijayawardana, Sameera
Moser, Brian
Urunuela, Arantxa
Wacheck, Volker
Harding, James J.
CANCER RESEARCH, 2017, 77
[9] A PHASE 1B/2 STUDY OF CABOZANTINIB IN COMBINATION WITH PEMBROLIZUMAB IN ADVANCED MELANOMA
Jain, Jayanshu
Frees, Melanie
Yasin, Hesham
Bonner, Jaime
Freesmeier, Michele
Garje, Rohan
Venur, Vyshak Alva
Milhem, Mohammed
Zakharia, Yousef
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A260 - A260
[10] Association of gBRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study
Yoshihara, Kosuke
Enomoto, Takayuki
Aoki, Daisuke
Watanabe, Yoh
Kigawa, Junzo
Takeshima, Nobuhiro
Inomata, Hyoe
Hattori, Kana
Jinushi, Masahisa
Tsuda, Hitoshi
Sugiyama, Toru
CANCER SCIENCE, 2020, 111 (09) : 3350 - 3358

← 1 2 3 4 5 →